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A Meta-Analysis of the Prevalence of Low Anterior Resection Syndrome 





To summarize the reported prevalence and causative f ctors of Low Anterior Resection 
Syndrome (LARS) from studies using the LARS score. 
 
Methods: 
A systematic literature search was conducted using Pubmed, Ovid Medline and the Cochrane 
database.  Searches were performed using a combination of MeSH (medical subject 
headings) terms and key terms.  Studies that were included used the LARS score as their 
primary collection tool.  Studies were excluded if in tial surgery was not for malignancy, or if 
the majority of LARS scores were from patients less than 1 year post initial surgery or 
closure of diverting stoma.  Eligible studies were assessed with a validated quality assessment 
tool prior to performing a meta-analysis with quality effects model.  Meta-analysis was 





















Following the initial search and implementation of inclusion and exclusion criteria 11 studies 
were deemed suitable for meta-analysis.  Meta-analysis found the estimated prevalence of 
major LARS was 41% (95% CI 34 -48).  Where possible outlier studies were excluded, the 
prevalence was 42% (95%CI 35-48).  Radiotherapy and tumour height were the most 
consistently assessed variables, both showing a consiste t negative effect on bowel function.  
Defunctioning ileostomy was found to have a statically significant negative impact on bowel 
function in 4 of 11 studies.  The majority of reported data has been produced by groups in 
Denmark and the United Kingdom with limited numbers p ovided by other locations.  
Available data is heterogenous with some variables having limited numbers, making meta-
analysis of certain variables impossible. 
 
Conclusions: 
There is significant prevalence of Low Anterior Resection Syndrome following oncological 
rectal resection.  A low anastomotic height or history of radiotherapy are major risk factors. 
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With advances in both surgical and adjuvant therapis for rectal cancer, there has been a 
decrease in the need for abdominoperineal resection (APR) with end colostomy.  Low 
anterior resection with total mesorectal excision (LAR) has become the preferred procedure 
in suitable patients with mid and low rectal cancers [1]. Since then, there has been an 
increasing recognition of Low Anterior Resection Syndrome (LARS) which includes 
incontinence (to faeces and flatus), urgency, diarrhoea, frequency and clustering of bowel 
motions [2,3].  Patients with LARS often experience either a pattern of urgency and 
incontinence, or alternately, obstructed defecation.  Bowel adaptation is thought to occur by 
about 18 months post operatively, after which, furthe  improvement with time is unlikely.  
This means that a proportion of patients will have permanent alteration in bowel function [4].    
Furthermore, with improved oncological outcomes, patients with persistent symptoms will be 
burdened with LARS into the longer term [5]. 
Currently the volume of literature related to this topic is growing, however there is variability 
of results with estimated prevalence of LARS ranging from 19-52% [6]. This variability 
arises from the use of different data collection tools which are not specific to LARS and often 
don’t take quality of life into consideration.  This has made any meta-analysis impossible.  
The LARS score was thus developed to allow for the collection of comparable data which 
would make such a meta-analysis possible and allow for a more accurate estimation of the 
true prevalence of LARS.  The LARS score is a validate  a scoring system which is specific 
















[3]. The aim of this review was to collate and analyse published data on the prevalence of 
LARS after 1 year follow-up, from studies which utilise the LARS score.  Risk factors 
continuing to contribute to LARS after 1 year were also assessed. 
 
2.0 Methods 
2.1 Database search 
The work has been reported in line with PRISMA (Preferr d Reporting Items for Systematic 
Reviews and Meta-Analyses) Guidelines.  A systematic literature search was conducted using 
Pubmed, Ovid Medline and the Cochrane database.  A date range for the search was set from 
2005 to March 2017.  Searches were performed using a combination of MeSH (medical 
subject headings) terms and key terms; “Low anterior resection syndrome”, “Anterior 
Resection syndrome”, “Prevalence”, “Incidence”, “bowel function”, “Quality of life” and 
“Low anterior resection syndrome score”.  All articles collected by the initial search were 
screened by title and abstract to determine their relevance to the study questions.  The 
bibliographies of relevant articles were cross referenced with the list of journals from the 
initial search and appropriate articles were subsequently added.   
2.2 Study selection 
The criteria for inclusion were primary studies which assessed prevalence of LARS using 
LARS score (Figure 2.) and assessed causative factors for LAR.  Only articles written in 
English were included.  Studies that were excluded i) used alternate data collection tools, ii) 
majority of functional data was from patients with period of intestinal continuity of less than 
















2.3 Quality Assessment 
Prior to meta-analysis the selected articles were critically assessed and scored using the 
validated quality assessment QUADAS2 tool, independently by 2 authors.   
2.4 Data Extraction 
The measured prevalence (percentage of population studied) of major, minor and no LARS 
was recorded for each study along with patient numbers and follow up period (see Table 1).  
Variables for systematic review including patient variables (age and gender) and treatment 
variables (anastomotic height, neoadjuvant therapy, nastomotic technique, anastomotic leak 
and duration of ileostomy) were recorded for each study, see (Tables 2 & 3).  
 
 
3.0 Statistical Analysis 
Meta-analysis was undertaken using a quality-effects model (factoring the QUADAS2 
scores) conducted using the MetaXL (www. epigear.com) add-in for Microsoft Excel. A 
pooled prevalence figure was calculated with 95% CI. We conducted the meta-analysis with 
prevalence estimates that had been transformed using the double arcsine method. This 
method avoids variance moving towards zero as a result of estimate of the study tending 


















The initial search identified 271 articles.  See figure I., for selection of final 11 articles.  
Using the quality assessment tool (QUADAS2) these 11 studies were found to be good 
quality however there were a number of weakness identified.  Although anastomotic height is 
one of the main recognised causative factors for LARS, it was only clearly described in the 
data of 3 studies [6-8].  Although all studies except 1 used LARS score data only for patients 
who had intestinal continuity for 12months or more, the exact time from initial surgery to 
closure of diverting stoma was poorly described in the majority of studies [3,7,9-12].  The 
form of anastomotic technique or pouch formation were also often not described in a large 
proportion of studies [1,3,9,11,13].  Of the 11 studies which met inclusion criteria, 5 were 
from Denmark or the United Kingdom (see Table 1) [1.7,9-11].  The largest patient numbers 
were also from these studies.   
The prevalence of LARS from these studies is shown (see Table 1), where major LARS has 
significant impact and minor and no LARS is considere  together as they both have minimal 
impact on quality of life.  All studies, with the exception of 2, [1,14] had a mean or median 
follow up of 18months or greater (see Table 1) indicating that the majority of questionnaire 
results would represent mid to long term function fllowing surgery.  The prevalence ranged 
widely from 17.8%-56%, and the estimated meta-analysis prevalence using the quality effect 
model was 41% (95% CI 34 -48), I2=91%, p<0.001(Table 4, Figure 3).  The study with the 
lowest rate of major LARS excluded patients who hadun ergone neoadjuvant therapy which 
has likely played a major role in the low rate of major LARS identified [6].  The same study 
also had a larger percentage of patients with tumours in the upper rectum (>40%) which 
again is known to reduce the risk of developing significant bowel disturbance post-
operatively.   Hughes et al included patients who had ad restoration of intestinal continuity 
for a minimum of only 12weeks, which is a potential reason for their higher rate of LARS 
















The same study also identified that the patient group who completed the survey <1yr 
following surgery had a mean LARS score of 35.5 compared to 27.9 which was the mean 
score found in patients completing the questionnaire >4years following surgery.  However, a 
sensitivityanalysis which excluded the studies by Ekkarat and Hughes found a prevalence rate 
of 42% (95%CI 35-48), which is close to the original meta-analysis prevalence. 
Radiotherapy used in either a neoadjuvant or adjuvant setting was the most consistently 
assessed variable affecting major LARS (see Table 2) and reached statistical significance in 8 
of the studies [1,3,6-9,12,13].  Hughes et al determined that neoadjuvant radiotherapy in their 
population was associated with a 20-fold increased risk of developing major LARS (p<0.01). 
Bondeven et al also found that neoadjuvant therapy was an independent risk factor for the 
development of major LARS (OR:3.5, 95% CI) even with a larger remnant rectum.  Ekkarat 
et al who excluded patients that had neoadjuvant therapy identified through multivariate 
analysis that post-operative radiotherapy was the only factor associated with major LARS 
(OR 6.5, 95% CI;2.37-18.15).   
Tumour height and hence anastomotic level was the second most commonly analysed 
variable and 6 of the 11 studies identified a statitically significant association with the 
development of major LARS [3,7-9,12,13].   Bondeven et al used post-operative Magnetic 
Resonance Imaging (MRI) to accurately assess remnant a stomotic height to assess its 
impact of post-operative bowel function. They found that the risk of major LARS was 46% in 
patients with less than 4cm of remnant rectum preserv d compared to 10% in patients with 
>4cm of remnant rectum preserved (P<0.0001).  Ekkarat et al correlated anastomotic level 
with major LARS to demonstrate that an anastomotic he ght of <5cm had a higher risk of 
















for the development of major LARS (adjusted OR for major LARS 2.31, CI;1.69-3.16) due to 
a likely associated low anastomotic height. 
Four studies (see Table 3) looked at the presence of an ileostomy and duration prior to 
reversal, all of which found an increased risk of major LARS [1,6,12,13].  Having a 
complication of an anastomosis, in particular an anastomotic leak, was consistently found to 
be associated with increased risk of developing major LARS and in one study this association 
was found to be significant [8].  Age was found to have a statistically significant association 
with the development of major LARS in only one study [13].  Sturiale et al found that having 
surgery at 70 years increased the risk of developing major LARS whilst most other studies 
found a trend in younger patients (<65 or 70yo) for developing major LARS which did not 
reach statistical significance [1,6,8,10-12,14].  None of these studies found any significant or 
consistent association between gender and the developm nt of LARS. 
 
5.0 Discussion 
Our meta-analysis showed a prevalence of persistent ig ificant (major) LARS of 41% with 
narrow 95% confidence levels of 34-48%, where the repo ted prevalence ranged widely from 
17.8-56%. This should raise the need of awareness of the condition and its morbidity.  This 
meta-analysis investigating the prevalence of LARS is the first of its kind and has been made 
possible by the creation of a validated data collection tool that is specific for patients with 
altered bowel habit following LAR.  Early literature investigating LARS used a variety of 
data collection tools which only reflected a component of the syndrome, such as 
incontinence, which would thus only identify a proportion of patients with LARS.  Also, the 
















be subjected to meta-analysis.  Therefore this study offers a more accurate representation of 
the prevalence of LARS as it has used a specific scoring system designed for this purpose.   
Although the studies reported from patient populations which are heterogenous for treatment 
and patient related factors, this nonetheless likely closely represents the patients after LAR 
presenting for clinic follow-up. The main limitation of the meta-analysis was that most of the 
larger studies were from Denmark and the United Kingdom.  As well as this, 3 of the studies 
from Denmark have been produced by the same institution with overlapping time periods, 
which may have resulted in same patient data being used in multiple studies. This may 
therefore not represent the overall worldwide LARS prevalence, and possibly the prevalence 
in any locality taking into account the possible impact of factors including diet and life-style 
adaptations to LARS which impacts upon the quality of life. Nonetheless, we hope that this 
review will generate interest in LARS prevalence studies over the world using the 
increasingly accepted standardized LARS score so that comparable results will be generated 
with a scoring system specific for LAR patients   
Our systematic review also showed that LAR patients may have undergone different 
variations in surgical technique, or reconstruction and adjuvant therapy regimes necessary for 
the complex management of rectal cancer. Radiotherapy and level of colorectal anastomosis 
were the most consistently reported factors to significantly negatively impact on major 
LARS. Radiation both preoperatively and post operatively have also been found to have 
negative effects on function in LAR patients with greater numbers of incontinent episodes 
and decreased rectal sensation [15].  The potential effects of radiation on the sphincter 
complex have been investigated and it is likely that reducing the dose leads to improvement 
in sphincter function post treatment [16].  With regard to the increased rates of major LARS 
in patients with a previous diverting ileostomy, the relationship is expected to be due to 
















ileostomy is used more commonly in lower resections, which is known to increase the risk of 
LARS, this would likely account for its association with major LARS.  Most treatment 
regimens for anastomotic leak involve having a divert ng ileostomy for a more prolonged 
period.  Since anastomotic leak has been identified as a risk for developing major LARS this 
association likely plays a major role in patients with long term ileostomies having worse 
bowel function once reversed.  A recent randomised control trial comparing LARS scores for 
patients treated with a temporary stoma and no stoma f und no statistical difference in major, 
minor and no LARS when comparing the 2.  The same study however found that patients 
treated with a temporary stoma more often reported incontinence for flatus and liquid stools 
and had a higher total LARS score [17.  The authors of this study conceded that data was still 
relatively preliminary and further confirmation studies are required. 
Although colonic adaption over a period of about 12months may improve bowel function, we 
confirm that a significant population of patients continue to suffer into the mid and long term. 
The cause of LARS is complex and likely multifactorial.  Impaired anal sphincter function 
has been identified in patients following LAR and has been shown to be associated with 
poorer functional outcome [2,6,18].  It is suspected that the resultant impairment of the anal 
sphincter could be due to both direct injury to the anal sphincter as well as damage to it 
innervation with pelvic dissection of the rectum [2,18].  Altered intestinal motility due to 
disruption of the parasympathetic innervation of the bowel has been suggested to play a role 
in the development of LARS [2,19].  Emmertsen et al found that a hyperactive postprandial 
response in the neorectum in non-irradiated TME patients likely played a significant role in 
the development of LARS and was potentially due to the denervation of the neorectum.  
Interestingly the same study found no significant differences in sphincter pressure between no 
LARS and Major LARS patients suggesting a more proximal cause of bowel dysfunction 
















further limitation of the metanalysis is the lack of definitive data regarding the pattern of 
LARS into the longer term. Further studies need to be conducted for follow-up LARS over 
time, particularly with improved long-term cancer su vival.   
Our review on the prevalence and morbidity of LARS suggests that the latter must be taken 
into appropriate consideration in the management of rectal cancer, although oncological 
considerations need to be prioritized.  Further investigating patient selection for neoadjuvant 
therapy and improving the sensitivity of investigaton techniques such as MRI may further 
improve patient selection and result in less post treatment morbidity [20].  In addition, partial 
mesorectal excision for upper rectal cancers where appropriate rather that total mesorectal 
excision should be adhered to as the oncological outcomes are equivalent and functional 
outcomes appear to be superior [21].  The use of rectal reservoirs to alleviate symptoms 
following LAR have been shown to improve function with decreased frequency and urgency 
of defecation [22], at least in the early postoperative period.  Prior to resection, patients also 
require counselling and education as to what their expected functional outcome may be.  A 
consent aid has been developed, which aims to predict post treatment functional outcome for 
rectal cancer patients based on what surgery, and or other treatment factors they will be 
receiving for their cancer [23].  Furthermore, there should be a sympathetic awareness and 
willingness to address LARS in postoperative follow-up rather than focussing only on 
oncological issues. Therapies such as biofeedback, s ral nerve modulation and rectal 
irrigation have been reported and are showing promise in improving patients anorectal 


















The estimated prevalence of major LARS in this meta-an lysis is 41% (95% CI 34 -48), at 1 
year after surgery.  Radiotherapy, whether pre or post-operative, and low tumour height are 
the 2 factors which have the greatest negative impact of patients bowel function following 
LAR.  The presence of a temporary stoma and having a stoma for a prolonged period of time 
are also associated with poorer bowel function. However, this is likely a reflection of the 
tumour height and possible complications of surgery which may also impact negatively on 
bowel function.  Further studies to better define th  prevalence in various parts of the world 
as well as to clarify the pattern of LARS over time with long term follow-up is required. 
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Study Patient Number Time from 
Surgery to 
Survey* 
Major LARS Minor LARS No LARS 





92.8% Mean follow up time 
55.5months 
190/478 (40%) 119/478 (25%) 169/478 (35%) 
Juul et al. 
2014, Denmark + UK 
579   80% Median follow up 4.9yrs 
(range 1.6-12.4yrs) 
214 (47%) 103 (23%) 134 (30%) 
Bondeven et al 
2015, Denmark 
125  100% Due to 
retrospective design 
Median follow up 
18months (range 12-
24months) 
47 (35%) 30 (24%) 48 (35%) 
Hain 
2016, France  
135 87% Median 43 (range 12-
117months) 
36 (23%) 68 (50%) 23 (31%) 
Bregendahl 
2013, Denmark 
1087  90.1% Median 54months (range 
25-97months) 
383 (41%) 221 (23.5%%) 334 (35.5%) 
Juul et al. 
2014, multicentre international  
Denmark, Spain, Sweden, 
Germany 
1061  76% Mean 5.6yrs (SEM 2.3) 414 (52%) 155 (19%) 227 (29%) 




100%  12months following 
reversal of ileostomy  
5 (23.8%) 4 (19%) 12 (57.1% 
Hughes  
2017, Wales 
85  80% Median 248days (range 17-
1664days) 
38 (56%) 12 (18%) 18 (26%) 
Carillo et al. 
2016, Spain 
195   70% Median 37months 62 (47%)  25 (18.9%)  45 (34.1%) 
Ekkarat et al.  
2016, Thailand 
 
129  Not discussed, 
however base on study 
design would be 
expected to be ~100% 
Median 38months (range 
11.7-117.5months) 
23 (17.8%) 22 (17%) 84 (65.4%) 
Sturiale  
2016, Italy 
110  84.5% Median 13.7yrs (range 
10.9-18yrs) 













Table 2.  Risk factors for LARS, Neoadjuvant therapy and Anastomotic Height 
 




Significant (p < 0.0001) 
Radiotherapy (20.6% of patients) risk factor for LARS 
 
 
Significant  - p < 0.0001 
tumour height > or < 5cm 
patient numbers not shown in data. 
Juul et al. 
2015, Denmark + UK 
 
Significant (p=0.018)  
Neoadjuvant (n: 141, median LARS: 30) 




<5cm from anal verge  (n=72, median LARS score 32) 
>5cm from anal verge (n=378, median LARS score 28) 
Bondeven et al 
2015, Denmark 
 
Significant (p= 0.002) 
Long course (n. 25/20%)  neoadjuvant  chemoradiation: 
independent risk factor for major LARS (OR: 3.5, 95% CI: 1.15-
9.4) 
 
Significant (p= 0.0001) 
<4cm remnant rectum: 46% risk of major LARS 
- n. 22/48 major LARS in <4cm 
 
 >4cm remnant rectum: 10% risk of major LARS 
- n. 5/47 major LARS in >4cm 
 
TME performed in anastomoses 2-8cm from anal verge 
PME performed in anastomoses 5-13cm from anal verge 
Hain 
2016, France  
 
Significant (p=0.0007) 
Long course radiotherapy (n.96/71%): independent risk factor for 
major LARS 
 
Risk factors for major LARS: 
intersphincteric resection (likely used to tumours <4cm) (p=0.003) 
 






Neoadjuvant  (n.96/9% short course, n.95/9% long course): 
increased risk of developing major LARS (OR 2.48; 95% CI: 
1.73-3.55) 
 
TME for lower cancers: increased risk of major LARS (OR= 2.31; 95% CI: 
1.69-3.16) 
TME n.555, tumours 0-10cm n.453 















Juul et al. 
2014, multicentre international  
Denmark, Spain, Sweden, 
Germany 
 
No statistical analysis discussed 
Radiotherapy (n.431/41%):  
major LARS (n.279) 
minor LARS (n.79) 
no LARS (n.73) 
 
 
No statistical analysis discussed 
Mean tumour distance from anal verge: 
 major LARS – 9 cm n.414/796 
 minor LARS – 9.6 cm n.155/796 
 no LARS  - 10.6 cm  n.227/796 
Luca et al 
2016, Italy 
 
No significant association with major LARS and long course 
neoadjuvant  (n.18/78%) 
*This was not displayed in the data 
 
No significant association with major LARS.  
 
All patients had tumours within 5cm of anal verge, mean 3.17cm 
 
  





Neoadjuvant radiation (n=19/22%): 20 fold increased risk of 
developing major LARS 
 
Not significant (p=0.37) 
Tumour < 8cm increased risk of major LARS (OR 1.6; 95% CI: 0.6-4.1) 
 
Major LARS Tumour <8cm n. 18/22 
Major LARS Tumour >8cm n. 20/34  




long course radiotherapy (n=30/48) developed  major LARS 
 
Significant (p<0.001) 
Risk factors for major LARS: 
TME n=56/91 
PME n=6/35 
* Did not discuss anastomotic/tumour height, however TME for middle and 
lower tumours, PME for upper rectal tumours 




Association of adjuvant radiotherapy and development of major 












Neoadjuvant radiotherapy n=13/19  
 
Significant p=0.003 
 Major LARS: 














Table 3.  Risk factors for LARS, Patient and Ileostomy Factors  
 










Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
Type of reconstruction not 
recorded in database 
Juul et al. 
2015, Denmark + 
UK 
 
Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
Not discussed 
Bondeven et al 
2015, Denmark 
 
No association found 
between major LARS 
and age 
 
No association found 
between major LARS and 
gender 
 
Anastomotic leak was an 
exclusion criteria 
 
Not discussed as possible 
causative factor 
End to side Vs End to End.  Not 
found to have significant 
impact. 
Hain 
2016, France  
 
Not significant (p=0.202) 
>70yo less likely to 
develop LARS (OR 0.49, 





Not significant (p=0.37) 
Males less likely to 





Significant (P= 0.02) 
Symptomatic anastomotic leak: 
independent risk factor for 
major LARS  
 
Not discussed as a possible 
causative factor 
Hand-sewn coloanal 
anastomosis greater risk of 
Major LARS p = 0.003 
 
Side to end anastomosis greater 
risk of developing major LARS 




< 64yo more likely to 
develop major LARS 
(OR= 1.9; 95% CI 1.43-
2.51) 
 
Females more likely to 
develop major LARS 
(OR= 1.35; 95% CI; 1.02-
1.79) 
 
Anastomotic leak increased risk 
of developing major LARS (OR 
2.06; 95% CI:0.93-4.55) 
 
Not discussed as possible 
causative factor 
Colonic pouch Vs straight-to-
end or side-to-end anastomosis  
 
 
No Statistical difference found 






No statistical analysis 
discussed 
The mean age of patients 
with: major LARS: 
66.4yo 
minor LARS: 68.3yo 
no LARS: 70.2yo  
 
No statistical analysis 
discussed 
Major LARS (n=414) 
males (n=232): 56% 
females (n=182) = 44% 
*55% of total patients 
male  
 
Not discussed as possible 
causative factor 
 















Luca et al 
2016, Italy 
 
No significant association 
with major LARS.   
*This was not displayed 
in the data 
 
No significant association 
with major LARS.   
*This was not displayed in 
the data 
 
Not discussed as possible 
causative factor 
 
Not discussed as possible 
causative factor 
All patients had hand-sewn 




Not significant (p=0.14) 
>70yo reduced risk of 
major LARS (OR 0.5; 
95% CI:0.2-1.3) 
 
Not significant (p=0.73) 
Male gender increased risk 
of developing LARS (OR 
1.2; 95% CI;0.4-3.5)  
 
Not significant (p=0.26) 
Anastomotic leak increased risk 




ileostomy closure after 1 year 
increased risk of major LARS 
(OR 3.7; 95% CI: 1.1-13.1) 
Not discussed 
Carillo et al. 
2016, Spain 
 
Not significant (p=0.45) 
Average age of: 
Major LARS - 69.1yo 
Minor LARS 66.3yo 
No LARS 68.3yo 
 






Not significant (p=0.641) 
Major LARS: 
With anastomotic complication 
n= 1/3 
With no anastomotic 
complication n=61/129 
 
* Reported anastomotic 






No diverting stoma n=19/59 
Diverting stoma n=43/73 
 
*Timing not discussed, however 
presence of stoma vs no stoma 
noted 
 
Lower rates of major LARS 
reservoir (colonic pouch or 
colopalsty) p= 0.017 
 
Ekkarat et al.  
2016, Thailand 
 
Not significant (p=0.72) 
Major LARS: 





Not significant (p=0.18) 
Major LARS: 
Males n=9/67  
Females n=14/62 
 





No diverting stoma n=11/88 
Diverting stoma n=12/41  
*Timing not discussed, however 
presence of stoma vs no stoma 
noted 
 
For ULAR (n. 38) 
27anastomosed with stapler, and 
11 with handsewn. 
 
Hand-sewn found to have 
















Median time of closure 
 of ileostomy:  
major LARS: 5.4 months minor 
LARS: 3.3  months 
no LARS: 2.6 months  




























Table 4. Meta-analysis results of LARS score prevalence 
 
 Major LARS Minor LARS No LARS 
















Figure 1 Flow chart of study selection. * Studies excluded as they did not primarily focus 
















Records identified through 
database searching 


































Records after duplicates removed 
(n = 158) 
Records screened 
(n = 158) 
Records excluded * 
(n = 118) 
Full-text articles assessed 
for eligibility 
(n = 40) 
Articles excluded due to 
use of alternate data 
collection tool other than 
LARS score 
(n = 29) 
Studies included in 
qualitative synthesis 





















































Ekkarat et al. 2016 
Sturiale 2016 
Luca et al 2016 
Hain 2016 





Carillo et al. 2016 
Juul et al. 2014 
Juul et al 2014 
Hughes 2017 
    Prev (95% CI)          % Weight
   0.18  (  0.12,  0.25)      5.3
   0.20  (  0.13,  0.29)      4.3
   0.22  (  0.07,  0.41)      2.6
   0.28  (  0.21,  0.37)      5.8
   0.38  (  0.29,  0.46)      5.2
   0.40  (  0.35,  0.44)     11.4
   0.41  (  0.38,  0.44)     23.9
   0.41  (  0.34,  0.48)    100.0
   0.47  (  0.38,  0.56)      5.3
   0.47  (  0.43,  0.52)     12.3
   0.52  (  0.49,  0.55)     20.5


















Ekkarat et al. 2016 
Luca et al 2016 
Hughes 2017 
Carillo et al. 2016 
Juul et al 2014 








    Prev (95% CI)          % Weight
   0.17  (  0.11,  0.24)      5.3
   0.17  (  0.04,  0.36)      2.6
   0.18  (  0.09,  0.28)      3.4
   0.19  (  0.13,  0.26)      5.3
   0.19  (  0.17,  0.22)     20.5
   0.23  (  0.19,  0.27)     12.3
   0.24  (  0.21,  0.26)     23.9
   0.24  (  0.17,  0.30)    100.0
   0.24  (  0.17,  0.32)      5.2
   0.25  (  0.21,  0.29)     11.4
   0.27  (  0.18,  0.36)      4.3




















Juul et al 2014 
Juul et al. 2014 





Bondeven et al 2015 
Luca et al 2016 
Sturiale 2016 
Ekkarat et al. 2016 
    Prev (95% CI)          % Weight
   0.18  (  0.12,  0.25)      5.8
   0.26  (  0.17,  0.38)      3.4
   0.29  (  0.25,  0.32)     20.5
   0.30  (  0.26,  0.34)     12.3
   0.34  (  0.26,  0.42)      5.3
   0.35  (  0.28,  0.42)    100.0
   0.35  (  0.31,  0.40)     11.4
   0.36  (  0.33,  0.39)     23.9
   0.38  (  0.30,  0.47)      5.2
   0.52  (  0.32,  0.72)      2.6
   0.53  (  0.42,  0.63)      4.3















• Low anterior resection syndrome (LARS) more common due high rates of sphincter 
preserving surgery  
• The LARS score was designed to make a meta-analysis of the syndrome possible 
• Risk factors need to be defined in order to attempt preventing LARS 
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